Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

Summary

The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurately predict OS and the use of this metric in other settings should now be explored. In the egalitarian system that is the VHA the treatment of prostate cancer is excellent and uniform across the US. The choices made are clearly personalized, given not all men received all therapies and that younger Veterans were treated more aggressively.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Metastatic Cancer
• Neoplasm, Prostate
• Castrate-sensitive
• Castrate-sensitive Prostate Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

Male

Healthy volunteers

Not accepted

Sponsor

Sun Pharmaceutical Industries Limited

Last updated on ClinicalTrials.gov

June 15, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites